J&J Brings Two-Year Psoriasis Data to Dermatology Meeting
Johnson & Johnson presented two-year psoriasis drug data at a dermatology meeting, extending long-term evidence for its inflammatory franchise as competition intensifies.
Topic
Long Term Data
Topic
Long Term Data
Nemolizumab Shows Sustained Response up to Three Years in Atopic Dermatitis
Long-term data report sustained nemolizumab response in moderate-to-severe atopic dermatitis patients treated for up to three yea…